Featured Research

from universities, journals, and other organizations

Biopharmaceutical Infrastructure Key To Lower Drug Development Costs

Date:
October 29, 2007
Source:
National Institute of Standards and Technology (NIST)
Summary:
Improvements to the technology infrastructure for researching and developing new biopharmaceuticals would be expected to save the industry hundreds of millions of dollars annually, according to a new economic study sponsored by NIST.

A new NIST-sponsored study found that the biopharmaceutical industry spend a total of $1,219 million on infrastructure technology?884 million on the R&D technology infrastructure including bioimaging, biomarkers, informatics, and gene expression and $335 million on infrastructure for commercial manufacturing and postmarket surveillance.
Credit: NIST

Improvements to the technology infrastructure for researching and developing new biopharmaceuticals would be expected to save the industry hundreds of millions of dollars annually, according to a new economic study* sponsored by the National Institute of Standards and Technology (NIST).

Prepared by RTI International for NIST, the study‘―s authors found that over the last two decades emphasis in new drug development has shifted from small-molecule chemicals to large-molecule proteins and other biopharmaceuticals such as human insulin, gene therapies and specialized antibiotic treatments. The report notes that the biopharmaceutical industry currently spends about $21 billion annually on research and development and has commercialized over 400 products.

Producing and maintaining the infrastructure that supports R&D, manufacturing and postmarket surveillance, including core data, methods, and standards used to determine the quality and efficacy of biopharmaceuticals, costs the industry a total of $1.2 billion annually, according to the report. The study focused on expenditures for four major categories of technical infrastructure: bioimaging, biomarkers, bioinformatics, and gene expression, as well as expenditures for infrastructure supporting processing and quality control for commercial manufacturing and activities involved with postmarket surveilliance. (See chart.)

According to the study, improvements to this infrastructure, such as better standardization of data collection and analysis, would be expected to save between 25 and 48 percent of R&D expenses for each new biopharmaceutical drug approved by the Food and Drug Administration. Better technical infrastructure is also projected to reduce the average development time per approved drug from 122 months to 98 months, a reduction of 20 percent. The study further estimated that total industry manufacturing costs could be reduced over the four major phases of manufacturing by $1.5 billion or 23 percent.

Data for the study were gathered from individual researchers and organizations including a survey of 44 technical experts whose companies represent 42 percent of the combined annual R&D spending and 49 percent of the combined annual R&D sales in biopharmaceuticals.

The ultimate beneficiaries of an improved biopharmaceutical infrastructure, wrote the study‘―s authors, "are patients who gain access to a broader array of novel therapies where development is supported by an effective technology infrastructure."

The full report, Economic Analysis of the Technology Infrastructure Needs of the U.S. Biopharmaceutical Industry, is available at: http://www.nist.gov/director/prog-ofc/report07-1.pdf.

* RTI International, Economic Analysis of the Technology Infrastructure Needs of the U.S. Biopharmaceutical Industry: Planning Report 07-01, August 2007, 201 pp.


Story Source:

The above story is based on materials provided by National Institute of Standards and Technology (NIST). Note: Materials may be edited for content and length.


Cite This Page:

National Institute of Standards and Technology (NIST). "Biopharmaceutical Infrastructure Key To Lower Drug Development Costs." ScienceDaily. ScienceDaily, 29 October 2007. <www.sciencedaily.com/releases/2007/10/071011164809.htm>.
National Institute of Standards and Technology (NIST). (2007, October 29). Biopharmaceutical Infrastructure Key To Lower Drug Development Costs. ScienceDaily. Retrieved July 24, 2014 from www.sciencedaily.com/releases/2007/10/071011164809.htm
National Institute of Standards and Technology (NIST). "Biopharmaceutical Infrastructure Key To Lower Drug Development Costs." ScienceDaily. www.sciencedaily.com/releases/2007/10/071011164809.htm (accessed July 24, 2014).

Share This




More Matter & Energy News

Thursday, July 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

TSA Administrator on Politics and Flight Bans

TSA Administrator on Politics and Flight Bans

AP (July 24, 2014) — TSA administrator, John Pistole's took part in the Aspen Security Forum 2014, where he answered questions on lifting of the ban on flights into Israel's Tel Aviv airport and whether politics played a role in lifting the ban. (July 24) Video provided by AP
Powered by NewsLook.com
Creative Makeovers for Ugly Cellphone Towers

Creative Makeovers for Ugly Cellphone Towers

AP (July 24, 2014) — Mobile phone companies and communities across the country are going to new lengths to disguise those unsightly cellphone towers. From a church bell tower to a flagpole, even a pencil, some towers are trying to make a point. (July 24) Video provided by AP
Powered by NewsLook.com
Algonquin Power Goes Activist on Its Target Gas Natural

Algonquin Power Goes Activist on Its Target Gas Natural

TheStreet (July 23, 2014) — When The Deal's Amanda Levin exclusively reported that Gas Natural had been talking to potential suitors, the Ohio company responded with a flat denial, claiming its board had not talked to anyone about a possible sale. Lo and behold, Canadian utility Algonquin Power and Utilities not only had approached the company, but it did it three times. Its last offer was for $13 per share as Gas Natural's was trading at a 60-day moving average of about $12.50 per share. Now Algonquin, which has a 4.9% stake in Gas Natural, has taken its case to shareholders, calling on them to back its proposals or, possibly, a change in the target's board. Video provided by TheStreet
Powered by NewsLook.com
Robot Parking Valet Creates Stress-Free Travel

Robot Parking Valet Creates Stress-Free Travel

AP (July 23, 2014) — 'Ray' the robotic parking valet at Dusseldorf Airport in Germany lets travelers to avoid the hassle of finding a parking spot before heading to the check-in desk. (July 23) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:  

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile iPhone Android Web
          Follow Facebook Twitter Google+
          Subscribe RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins